奥希替尼耐药也有效! 靶向治疗是驱动基因阳性的NSCLC患者的首选治疗方案,免疫治疗是驱动基因阴性NSCLC患者的首选治疗方案,两种疗法一直分庭抗礼,对于驱动基因阳性的NSCLC患者,临床上一般不推荐免疫治疗。但是靶向药物不可避免的出现耐药情况,EGFR突变患者...
奥希替尼耐药也有效! 靶向治疗是驱动基因阳性的NSCLC患者的首选治疗方案,免疫治疗是驱动基因阴性NSCLC患者的首选治疗方案,两种疗法一直分庭抗礼,对于驱动基因阳性的NSCLC患者,临床上一般不推荐免疫治疗。但是靶向药物不可避免的出现耐药情况,EGFR突变患者使用三代EGFR-TKI奥希替尼耐药后无药可用,免疫治疗能否有效呢?Lung ...
Yeo JC, Takano A, Ong BH, Tan EH, Tan SH, Skanderup AJ, Tan DSW. PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer. Eur J Cancer. 2022 Oct 20;178:
1. Rathi N. Pillai et al,Comparison of the Toxicity Profile of PD-1 Versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature.2017 2. Monica Khunger et al. Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung can...
1.Singh N, Seetharamu N. Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer. BMJ Case Rep. 2020;13(8):e236101. Published 2020 Aug 24. doi:10.1136/bcr-2020-236101...
[1]Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021 Sep 17:S0140-6736(21)02098-5. doi: 10.1016/S0140-6736(21)020...
Non-small cell lung cancer (NSCLC) has constituted over 80% of the lung cancer population with a poor prognosis. Over the past decade, immunotherapy has been constructed in the enlargement of immune checkpoint inhibitors as a promising approach for NSCLC treatment. Evading the immune system using...
但对于无上市靶药可用(如KRAS突变)以及靶药耐药后的患者,用PD1/PDL1治疗的疗效究竟如何?各靶点对免疫治疗的效果是否一致?有何预测指标?这些问题临床多具争议。小编以一篇真实世界的PD1使用情况给大家探讨各个突变的疗效如何,为临床使用PD1提供适用人群参考及小指导建议。
3. Durvalumab as third-line or latertreatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label,single-arm, phase 2 study 4. ALT-803, an IL-15 superagonist, incombination with nivolumab in patients with metastatic non-small cell lungcancer: a non-randomised, open-label, ph...
参考: Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label,single-arm, phase 2 study。